Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.

Trial Details

NCT ID
NCT03467360
Phase
PHASE1
Sponsor
Centre Antoine Lacassagne
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • acetazolamide in combination with platinum and etoposide-based radiochemotherapy
  • acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Locations (sample)
  • Nice, France|43.70313,7.26608
  • Monte Carlo, Monaco|43.73976,7.42732

Key Eligibility Criteria

  • Age \> or = 18 years,
  • Performance Status 0 to 2,
  • Patient with an histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer,
  • Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group) or Patient who rece…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →